drugset / Trial / NCT07225504
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
Timeline
- Start
- 2025-11-11
- Primary completion
- 2030-12-03
- Completion
- 2034-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remibrutinib | Small molecule | — | Oral |